+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Investigation Report on China's Amlodipine Market, 2018-2022

  • ID: 4719957
  • Report
  • December 2018
  • Region: China
  • 30 pages
  • China Research & Intelligence
1 of 4
In 2017, the Market Size of Amlodipine in China was About CNY 730 Million says 2018 Report

FEATURED COMPANIES

The incidence of hypertension is increasing in China with the development of the economy, the change of lifestyle and the aging of the population. It is estimated that at the end of 2017, there were about 330 million hypertensive patients in China, i.e., one in every three Chinese adults has high blood pressure. With the increasing number of hypertensive patients, the market size of antihypertensive drugs is also growing.

Amlodipine is a third-generation calcium antagonist used to treat chronic stable angina and hypertension. It can reduce the risk of hospitalization for angina and the risk of coronary reacquainting. The brand-name Amlodipine is Pfizer’s Norvasc. In 1989, Amlodipine tablets were launched in the U.K. under the trade name Istin, and Amlodipine capsules were launched in Belgium under the trade name Amlor. In 1992, Norvasc was approved by the FDA as a new molecular entity (NME).

According to the report, after Amlodipine entered China, the market size of Amlodipine kept rising until 2013. From 2013 to 2017, however, the sales revenue declined because of the fall in average price and the competition from other antihypertensive drugs. Apart from Pfizer's Norvasc, generic drugs by Chinese companies have been marketed successively. The CFDA has issued dozens of Amlodipine production approvals, which means that there are dozens of Amlodipine manufacturers on the market. But the market is still dominated by Pfizer’s brand-name drug. In 2017, the market size of Amlodipine in China was about CNY 730 million. By sales value, the market share of Pfizer exceeded 80%. The other major market players were Yangtze River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd., China Resources Saike Pharmaceutical Co., Ltd., Kunming Sinoway Natural Pharmaceuticals, and Suzhou Dawnrays Pharmaceutical Co., Ltd.

It is expected that as the incidence of hypertension continues to increase, China's Amlodipine market will still have some growth potential in the next few years.

Topics Covered:

  • Situation of hypertension in China
  • Sales of Amlodipine in China
  • Competition on China's Amlodipine market
  • Prices of Amlodipine in China from 2017 to 2018
  • Factors influencing the development of China's Amlodipine market
  • Prospect of China's Amlodipine market
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

1 Relevant Concepts of Amlodipine
1.1 Indications for Amlodipine
1.2 Development of Amlodipine in China
1.3 Governmental Approval of Amlodipine in China

2 Sales of Amlodipine in China, 2013-2017
2.1 Sales Value of Amlodipine
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Amlodipine
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Amlodipine by Dosage Form in China, 2013-2017
2.3.1 Capsules
2.3.2 Tablets
2.3.3 Pills

3 Analysis on Major Amlodipine Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Amlodipine Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Pfizer
3.2.1 Profile of Pfizer
3.2.2 Sales of Pfizer's Amlodipine in China
3.3 Yangtze River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.
3.3.1 Profile of Yangtze River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.
3.3.2 Sales of Yangtze River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.'s Amlodipine in China
3.4 China Resources Saike Pharmaceutical Co., Ltd.
3.5 Kunming Sinoway Natural Pharmaceuticals
3.6 Suzhou Dawnrays Pharmaceutical Co., Ltd.

4 Prices of Amlodipine in China, 2017-2018
4.1 Pfizer (Norvasc)
4.2 Yangtze River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd. (Landi)
4.3 China Resources Saike Pharmaceutical Co., Ltd. (Yashida)
4.4 Kunming Sinoway Natural Pharmaceuticals (Xinluoping)
4.5 Suzhou Dawnrays Pharmaceutical Co., Ltd. (Anneizhen)

5 Prospect of China's Amlodipine Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

Selected Charts
Chart Governmental Approval of Amlodipine in China
Chart Sales of Amlodipine in China, 2013-2017
Chart Sales Value of Amlodipine in Parts of China, 2013-2017
Chart Sales Volume of Amlodipine in China, 2013-2017
Chart Sales Volume of Amlodipine in Parts of China, 2013-2017
Chart Sales Value of Amlodipine Capsules in China, 2013-2017
Chart Sales Volume of Amlodipine Capsules in China, 2013-2017
Chart Sales Value of Amlodipine Tablets in China, 2013-2017
Chart Sales Volume of Amlodipine Tablets in China, 2013-2017
Chart Sales Value of Amlodipine Pills in China, 2013-2017
Chart Sales Volume of Amlodipine Pills in China, 2013-2017
Chart Market Share of Top 5 Amlodipine Manufacturers by Sales Value in China, 2013-2017
Chart Market Share of Top 5 Amlodipine Manufacturers by Sales Volume in China, 2013-2017
Chart Sales Value of Pfizer's Amlodipine in China, 2013-2017
Chart Sales Volume of Pfizer's Amlodipine in China, 2013-2017
Chart Sales Value of Yangtze River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.'s Amlodipine in China, 2013-2017
Chart Sales Volume of Yangtze River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.'s Amlodipine in China, 2013-2017
Chart Sales Value of China Resources Saike Pharmaceutical Co., Ltd.'s Amlodipine in China, 2013-2017
Chart Prices of Pfizer's Amlodipine in Parts of China, 2017-2018
Chart Prices of Yangtze River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.'s Amlodipine in Parts of China, 2017-2018
Chart Prices of China Resources Saike Pharmaceutical Co., Ltd.'s Amlodipine in Parts of China, 2017-2018
Chart Prices of Kunming Sinoway Natural Pharmaceuticals' Amlodipine in Parts of China, 2017-2018
Chart Prices of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Amlodipine in Parts of China, 2017-2018
Chart Forecast on Sales Value of Amlodipine in China, 2018-2022

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • China Resources Saike Pharmaceutical Co., Ltd. (Yashida)
  • Kunming Sinoway Natural Pharmaceuticals
  • Pfizer
  • Shanghai Haini Pharmaceutical Co., Ltd.
  • Suzhou Dawnrays Pharmaceutical Co., Ltd.
  • Yangtze River Pharmaceutical Group
Note: Product cover images may vary from those shown
5 of 4

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...

Adroll
adroll